Atkinson M, Lansdown A J
Singleton Hospital, Swansea, UK.
University Hospital of Wales, Cardiff, UK.
Best Pract Res Clin Endocrinol Metab. 2022 May;36(3):101635. doi: 10.1016/j.beem.2022.101635. Epub 2022 Feb 28.
Immune checkpoint inhibitors are being prescribed increasingly widely for a range of malignancies. They are effective at treating certain cancers, but also have significant side effects. Evidence suggests that efficacy is greatest in patients who experience one or more immune-related adverse events (irAEs). Common irAEs include skin and hepatic reactions, and a range of immune-related endocrinopathies. These include hypophysitis, thyroid disease, and autoimmune diabetes mellitus, and rarer endocrinopathies such as primary adrenal insufficiency, diabetes insipidus, parathyroid disease, autoimmune polyglandular syndrome, lipodystrophy, and ACTH-dependent Cushing's syndrome. Herein, we review the current literature related to these rarer immunotherapy-induced endocrinopathies.
免疫检查点抑制剂正越来越广泛地用于治疗多种恶性肿瘤。它们对某些癌症有效，但也有显著的副作用。有证据表明，在经历一种或多种免疫相关不良事件（irAE）的患者中疗效最佳。常见的irAE包括皮肤和肝脏反应，以及一系列免疫相关的内分泌疾病。这些疾病包括垂体炎、甲状腺疾病和自身免疫性糖尿病，以及较罕见的内分泌疾病，如原发性肾上腺功能不全、尿崩症、甲状旁腺疾病、自身免疫性多腺体综合征、脂肪营养不良和促肾上腺皮质激素依赖性库欣综合征。在此，我们综述了与这些较罕见的免疫治疗引起的内分泌疾病相关的当前文献。
